XY25028 is an orally active LRH-1 inhibitor with an IC50 of 0.30 µM. XY25028 inhibits the proliferation of androgen receptor (AR)-positive prostate cancer cells and suppresses the expression of AR target genes KLK2 and KLK3. XY25028 can be used in the research of castration-resistant prostate cancer[1].
Molekulargewicht:
498.66
Formel:
C32H38N2O3
Target-Kategorie:
Androgen Receptor,c-Myc,Orphan Nuclear Receptor
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
